SUNESIS PHARMACEUTICALS INC's ticker is SNSS and the CUSIP is 867328700. A total of 6 filers reported holding SUNESIS PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $38,000 | +40.7% | 145,331 | +129.8% | 0.00% | – |
| Q1 2020 | $27,000 | +28.6% | 63,251 | +1.4% | 0.00% | – |
| Q4 2019 | $21,000 | -4.5% | 62,371 | +108.6% | 0.00% | – |
| Q3 2019 | $22,000 | -24.1% | 29,900 | -25.5% | 0.00% | – |
| Q2 2019 | $29,000 | -23.7% | 40,144 | +31.0% | 0.00% | – |
| Q1 2019 | $38,000 | +280.0% | 30,648 | +35.6% | 0.00% | – |
| Q4 2018 | $10,000 | -83.3% | 22,610 | -23.8% | 0.00% | – |
| Q3 2018 | $60,000 | +17.6% | 29,686 | +23.7% | 0.00% | – |
| Q2 2018 | $51,000 | -1.9% | 24,003 | +23.6% | 0.00% | – |
| Q1 2018 | $52,000 | +271.4% | 19,427 | +401.1% | 0.00% | – |
| Q4 2017 | $14,000 | -17.6% | 3,877 | -55.1% | 0.00% | – |
| Q3 2017 | $17,000 | +325.0% | 8,634 | +377.3% | 0.00% | – |
| Q2 2017 | $4,000 | 0.0% | 1,809 | +101.0% | 0.00% | – |
| Q1 2017 | $4,000 | -42.9% | 900 | -55.8% | 0.00% | – |
| Q4 2016 | $7,000 | +75.0% | 2,034 | +129.1% | 0.00% | – |
| Q3 2016 | $4,000 | – | 888 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 7,600,000 | $9,234,000 | 7.03% |
| Samsara BioCapital, LLC | 3,750,000 | $4,556,000 | 3.58% |
| CAXTON CORP | 277,245 | $337,000 | 0.31% |
| BVF INC/IL | 2,287,860 | $2,780,000 | 0.31% |
| Eventide Asset Management | 5,965,455 | $7,248,000 | 0.25% |
| Telemetry Investments, L.L.C. | 197,564 | $240,000 | 0.12% |
| NEA Management Company, LLC | 1,298,274 | $1,584,000 | 0.08% |
| RP Management, LLC | 129,517 | $158,000 | 0.08% |
| Palo Alto Investors LP | 1,162,473 | $1,412,000 | 0.06% |
| Fosun International Ltd | 725,000 | $863,000 | 0.06% |